Last updated: February 4, 2026
Case Overview
Catalyst Pharmaceuticals, Inc. (Plaintiff) filed a patent infringement lawsuit against Inventia Healthcare Limited (Defendant) in the District of Delaware on March 3, 2023. The case number is 1:23-cv-01331. Catalyst alleges that Inventia's generic formulations infringe on U.S. Patent No. 10,569,987, which covers an extended-release formulation of amifampridine.
Timeline and Procedural Posture
- Complaint Filed: March 3, 2023
- Defendant’s Response: Pending
- Preliminary Motions: None filed as of the latest update
- Pleadings Stage: Complaint only; no defendant filings or motions reported
Patent Details
- Patent Number: 10,569,987
- Issue Date: February 25, 2020
- Title: Extended-release formulation of amifampridine
- Patent Holder: Catalyst Pharmaceuticals, Inc.
- Claims: Cover specific extended-release formulations, including particular ratios, excipients, and manufacturing processes designed to optimize bioavailability and reduce side effects.
Legal Allegations
Catalyst alleges that Inventia's generic product, marketed as [product name pending], infringes claims 1-12 of the '987 patent by:
- Utilizing a similar extended-release formulation
- Employing manufacturing methods within the scope of the patent claims
- Selling the product in the United States without license or authorization
The complaint requests injunctive relief, damages for patent infringement, and attorneys' fees.
Defendant's Position (Pending)
Inventia has not yet filed an answer or asserted counterclaims. It likely will dispute the validity of the '987 patent or challenge its infringement.
Litigation Risks and Strategic Considerations
- Patent Validity Challenges: Inventia may seek to invalidate the patent through prior art, obviousness, or patentability arguments. Catalyst and Inventia have previously engaged in patent litigation for similar formulations, raising contentious issues.
- Infringement Defense: Inventia might argue non-infringement based on formulation differences or manufacturing methods.
- Settlement and Licensing: Given the patent's market significance, settlement could involve licensing agreements or patent buyouts.
Market and Regulatory Context
- Catalyst’s '987 patent forms part of a broader strategic patent portfolio for its Emflaza (deflazacort) franchise and other neurological therapies.
- The patent covers a critical segment of the extended-release amifampridine market, used for treating Lambert-Eaton myasthenic syndrome (LEMS).
Legal Environment and Patent Strategies
- Similar proceedings in the district courts, especially Delaware, often involve extensive claim construction and validity reexamination.
- Catalyst’s enforcement history exhibits a focus on securing patent rights and deterring generic competition.
Potential Outcomes
- Infringement Finding: Could lead to an injunction against Inventia's product launch or distribution.
- Invalidity Ruling: Could permit Inventia to market its generic product without license obligations.
- Settlement: Most patent cases resolve through licensing or settlement agreements.
Related Cases and Industry Trends
- Catalyst engaged in prior litigation related to amifampridine formulations, including patent challenges and settlement agreements (e.g., Catalyst Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc.).
- The industry pattern emphasizes proactive patent enforcement to preserve revenue streams amid patent expiration timelines.
Key Litigation Factors
| Factor |
Impact |
Notes |
| Patent strength |
Critical |
Claims are broad, covering formulations and processes |
| Infringement likelihood |
High |
Similar formulations used by generic companies |
| Validity challenges |
Probable |
Patentability defenses likely in procedural stages |
| Market significance |
High |
Amifampridine formulation patents crucial for Catalyst |
Citations
- Complaint filed in District of Delaware, March 3, 2023.
- Patent No. 10,569,987 (issued Feb. 25, 2020).
- Catalyst Pharmaceuticals, Inc., "About Us," [company website].
- Industry reports on amifampridine marketplace, 2022.
Key Takeaways
- Catalyst’s patent infringement suit against Inventia targets extended-release amifampridine formulations.
- The case underscores strategic patent enforcement in neurological drug markets.
- Validity and infringement are the focal points; both sides likely to engage in procedural battles.
- The case’s resolution will influence the competitive landscape for generic amifampridine products.
- Patent dispute outcomes will inform market access and royalty strategies in the neurological therapeutics sector.
FAQs
-
What are the main claims of Patent No. 10,569,987?
It covers specific extended-release formulations of amifampridine and manufacturing processes designed to improve patient safety and compliance.
-
What defenses could Inventia raise?
Challenges may include invalidity based on prior art, non-infringement due to formulation differences, or patent indefiniteness.
-
How does this case compare to previous Catalyst patent litigations?
It continues Catalyst’s enforcement pattern for neurological drug patents, especially formulations that extend exclusivity and market share.
-
What are the possible timelines for resolution?
Patent cases in Delaware typically last 1-3 years; the timeline depends on motions, discovery, and potential settlement.
-
How could this case affect the broader market?
If Catalyst prevails, it could delay generic entry, maintaining higher prices. A ruling favoring Inventia may accelerate generics’ market access.
Sources
[1] Complaint, Catalyst Pharmaceuticals, Inc. v. Inventia Healthcare Limited, D. Del., 1:23-cv-01331, Mar. 3, 2023.
[2] U.S. Patent No. 10,569,987.
[3] Catalyst Pharmaceuticals official site.
[4] Industry market reports, 2022.
